NuVasive (NASDAQ GS:NUVA) Not For The Faint Of Heart
NuVasive Inc. (
NASDAQ GS:NUVA) is an interesting smallish cap medical device company I've followed for a long time. She is not for the feint of heart - and this stock's reaction around earnings season is why earnings are the best of times / worst of times for me. I love the new data points; I hate the raging stampede of lemmings over reacting.
This chart alone shows you the "full round" trip you've encountered in the past 2 earnings reports - did business really change that much at all during this time?
No. But if you were an unfortunate owner 3 months ago you were dismembered... or if you were a lucky soul who decided to ignore a lousy chart and just buy in, you were rewarded handsomely last week with a gain of nearly 30% in 2 sessions. And for all that - you basically are back to where you were before the 2 earnings reports.
We were
out of the stock before the swoon, only because the chart was acting quite bad - but either way, this is the type of action that will destroy the accounts of both shorts and long if you are around for the wrong 1-2 days.
A quick look at the latest earning report and what made everyone "happy" again.
- The company lost $4.3 million, or 12 cents per share, compared with a loss of $7.7 million, or 22 cents per share, during the same period a year prior. Revenue rose 56 percent to $80 million from $51.2 million. Excluding charges for litigation and buyouts, the company said it lost 2 cents per share. Analysts polled by Thomson Reuters expected a loss of 20 cents per share on revenue of $74.8 million.
- The company boosted its full-year outlook, partly citing Osteocel sales. It now expects profit between 11 cents and 13 cents per share, up from prior guidance of 2 cents to 4 cents per share. That figure excludes litigation and buyout charges.
- Revenue is now expected to range from $355 million to $360 million, up from prior guidance $345 million to $350 million.
Related Stories
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
